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Abstract: Hip dysplasia is a significant public health issue, representing the single largest 
cause for total hip arthroplasty in young adults. To gain insight into patient concerns and the 
impact of hip dysplasia on young adults, we developed a patient-centred outcome measure, 
the ‘Quality of Life Impact and Concerns’ (QoLI&C) measure. This short report provides 
additional evidence on test–retest reliability and suggests refinements to the measure to 
enhance its research and clinical utility. 
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Hip dysplasia is a significant public health issue, representing the single largest 
cause for total hip arthroplasty in young adults.1 Acetabular dysplasia (AD) in 
young adults arises from residual childhood developmental dysplasia of the hip 
(DDH) and adolescent-onset acetabular dysplasia.2 Significantly, these young adults 
are experiencing chronic pain, insomnia,3 difficulty in walking and effects on social 
relationships at a time when they would normally be going to university, starting 
a career and/or having a family.4 To provide insight into patient-perceived and 
patient-significant concerns of hip dysplasia and its impact on everyday life, we 
developed a novel measure, the “Quality of Life Impact and Concerns” (QoLI&C) 
measure, and provided evidence on its psychometric features, in particular, its 
acceptability to patients, face and content validity, reliability and supportive evi-
dence of construct validity.5
This short report provides additional evidence to support the validity of the 
QoLI&C measure, exploring its test-retest reliability. The report also draws atten-
tion to some deficiencies in the published measure, namely, repeated or similarly 
phrased or poorly phrased items. The revised measure is presented, along with ways 
to best use the measure to enhance its research and clinical utility.
Test–Retest Study
A small test-retest reliability study (n=53) was conducted recruiting participants 
predominantly from volunteer patients taking part in a “human movement” PhD 
study* being conducted at Cardiff University’s Human Gait Laboratory. Study 
participants were recruited from a message posted on social media hip-dysplasia 
websites (Facebook - hip dysplasia; Facebook - International Hip Dysplasia 
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Institute) and two UK hip dysplasia charities (STEPS, 
DDH UK). This directed interested persons to information 
about the project located on a secure Cardiff University 
website. Participants were asked to complete the measure 
on two occasions, separated by 2–3 weeks. Participants 
firstly consented on-line to take part and then were direc-
ted to the measure. One of the research team (first author) 
then electronically re-contacted the participant 2 to 3 
weeks after the first questionnaire was completed and 
provided a link to the “retest” questionnaire. The two 
questionnaires were identical in all respects save two. 
Firstly, the “test” (first) questionnaire asked the participant 
two opened questions relating, respectively, to their hopes 
and fears. Participants commonly provided extensive com-
ments. These two questions were omitted from the “retest” 
(second) questionnaire, as it was perceived inappropriate 
and too onerous for a participant to complete them again 
just 2–3 weeks after completing the original questionnaire. 
Secondly, to enhance validity, the “retest’ questionnaire 
included two extra questions asking: (1) if there have 
been any changes in their quality of life and well-being 
because of their hip condition in the last 2–3 weeks; and, 
(2) if so, to outline what these were. To assess test-retest 
reliability, Pearson’s correlation coefficients were com-
puted. Ethical approval was gained from Cardiff 
University.
Participants had all been diagnosed with hip dysplasia 
(Table 1). Their profile was similar to those of participants 
in the original validation study.5 Just over a half (55%) had 
dysplasia in the left hip, and 28% in both hips. Participants 
were predominantly female (75%), had a median age of 28 
years (range, 19–56), and commonly were in full or part- 
time work (49%) or in further or higher education (30%). 
The median time from first concern over their hip condi-
tion to diagnosis was 2–5 years (mean, 3.4 years), but for 
19% it was five or more years. Nearly all (96%) had 
consulted a primary care physician prior to diagnosis and 
66% a physiotherapist. The majority were over 12 months 
post-surgery (left hip, 57%; right hip, 42%). The most 
common treatment for the left hip was joint conservation 
or triple/femoral osteotomy (64%). The most common 
treatment or the right hip was the “other” category 
(43%), involving a number of different treatments experi-
enced over time, followed by joint conservation or triple/ 
femoral osteotomy (21%).
Table 2 presents the test-retest results. For all the sub- 
scales and the overall QoLI&C measure, Pearson’s corre-
lations for the two time points ranged from 0.892 to 0.968, 
interpreted as evidence of “good” reliability.6 This was 
also the case for “current level of pain” and questionnaire 
completion time. “Acceptable” reliability, with values of 
0.736 to 0.736, was found for “satisfaction with care” and 
general health status. Looking overall, this small study 
provides supportive evidence on the test-retest reliability 
of the measure. None of the participants pointed to any 
change in their condition between completion of the “test” 
and the “retest” questionnaire.
Refinements to the Measure to 
Enhance Clinical and Research 
Validity
Our further research suggested ways to refine the measure 
to increase both its clinical and research utility. These were 
of three kinds.
Firstly, on close inspection of the published measure,5 
two unintentionally repeated item were found, one in 
Question 12 relating to the Pain sub-scale (“The aches 
and pains have become more frequent and more painful”), 
the other in Question 21 relating to the Quality of Life 
sub-scale (“My life is very disrupted by my hip condi-
tion”). This repetition has been removed. Secondly, two 
very similar questions were included in Question 14 as 
part of the Sports and Exercise sub-scale (“I want to stay 
fit and in shape, but because of my hip it has become 
harder and harder to find activities I can do” and “I want to 
keep trim and in shape but it has got harder and harder to 
find activities that I can do.”) The latter statement alone 
has been included in the revised questionnaire. Thirdly, 
a single “indignity of being young and having to be careful 
about what clothes and shoes to wear” was created within 
the Body Image sub scale. This replaced the previous two 
gender-specific items, asking female and male respondents 
respectively, “there is an indignity of being a young 
woman and not being able to go out, wearing heels and 
doing normal stuff” or “there is an indignity of being 
a young man and not being able to go out, play sports 
and doing normal.”
The revised measure, and associated on-line question-
naire**now comprises nine domains: Pain (10 items); 
Education and Work (3 items); Sports and Exercise (6 
items); Family Life (3 items); Physical Intimacy (3 items); 
Social Life and Relationships with Others (5 items); 
Confidence and Social Esteem (6 items); Body Image (9 
items); Emotion and Depression (7 items); and Overall 
Quality of Life (13 items). The wider questionnaire also 
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includes: fixed choice questions relating to levels of pain, 
satisfaction with treatment and general health status; two 
open-ended questions relating to hopes and fears; an open- 
ended question on the potential usefulness of the measure in 
discussions with their clinicians; and a rating of the ease of 
completion the measure and time taken to complete it. [see 
Supplementary Materials]
The measure is intended to be used by persons aged 16 
or over who have been diagnosed with hip dysplasia. All 
of the sub-scales bar one are appropriate for any such 
respondent. The one exception is the Physical Intimacy 
sub-scale, which is to be completed only by those aged 18 
or more. Where a respondent is aged under 18, this sub- 
scale would be omitted in the computation of the QoLI&C 
measure, thus resulting in a 62-item measure. For all other 
respondents, the full 65-item scale would be computed.
We suggest that the 65- or 62-item measure, dependent 
on age, can valuably be used by persons with hip dysplasia 
in their interactions with healthcare practitioners, includ-
ing those in primary care, to aid discussions and insight 
into the ways that hip dysplasia is affecting their everyday 
life. However, it is likely to be the case that patients in 
these interactions want to draw attention to particular 
issues, such as pain, emotional and social impact or quality 
of life, that is, either a particular sub-scale of the measure 
Table 1 Respondent Characteristics **
Variable Test–Retest Reliability 
(n=53)
Diagnosed Condition n = 53 (100%)
DDH in Both Hips 15 (28%)
DDH in Left Hip 29 (55%)
DDH in Right Hip 9 (17%)
Age (years)
Mean (Standard Deviation) 31.4 (10.5)
Median (Range) 28.0 (19–56)
Aged under 20 2 (4%)
Aged 20-<35 35 (66%)







Gender by Age Age < 20 Age 20-<35 Age ≥35
Female 0 26 14
Male 2 9 2
Job Status: (n=53)
Employed (full > 30 hrs) 19 (36%)
Employed (part-time) 7 (13%)
In Further/Higher Education 16 (30%)
At School 2 (4%)
Looking after Family 3 (6%)
Unemployed 1 (2%)
Not Working due to Ill-Health 4 (8%)
Other 1 (2%)







Female 21 12 7
Male 5 6 2
Stage of Treatment: 
Left Hip
(n=42)
Deciding on Treatment 6 (14%)
Waiting for Surgery 5 (11%)
Up to 12 Months Post-Op 7 (17%)
Over 12 Months Post-Op 24 (57%)
Type of Surgery: 
Left Hip
(n =53)
Joint Conservation or Triple/ 
Femoral Osteotomy
34 (64%)
Resurfacing Surgery 6 (11%)
Total Hip Replacement 11 (21%)
Other– Combination of 
Treatments over Time
2 (4%)
Do not Know 0
(Continued)
Table 1 (Continued). 
Variable Test–Retest Reliability 
(n=53)
Stage of Treatment: 
Right Hip
(n=24)
Deciding on Treatment 7 (29%)
Waiting for Surgery 3 (13%)
Up to 12 Months Post-Op 4 (17%)
Over 12 Months Post-Op 10 (42%)
Type of Surgery: 
Right Hip
(n = 46)
Joint Conservation or 
Triple/Femoral Osteotomy
10 (21%)
Resurfacing Surgery 3 (6%)
Total Hip Replacement 7 (15%)
Other – Combination of 
Treatments over Time
20 (43%)
Do not Know 6 (13%)
Note: **The total number of cases varies due to non-response to particular items 
and total % may not add up to 100% due to rounding. 
Abbreviations: DDH, developmental dysplasia of the hip; Post-Op, post 
operation.
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or particular items within a sub-scale. The actual value of 
the full measure may then be of lesser interest, except 
perhaps as a way for the individual to monitor changes 
over time, for example, due to treatment or felt greater 
impact of hip dysplasia on their life.
From a research and clinical utility perspective, the 
actual scores of the measure are likely to be most valuable 
as a way to provide an overview, summary of changes in 
the patient’s hip condition and/or to monitor both changes 
over time and the effect of different surgical and rehabili-
tation treatments. Potential time points for data collection 
relate, for example, to document changes over time from 
diagnosis onwards, or at post-surgery follow-ups, usually 
undertaken in the UK at 8 weeks, 3 months, 6 months and 
12 months (at which point patients would generally be 
discharged), and re-using the measure if and when patients 
re-enter any further hip-related healthcare, surgical inter-
vention or rehabilitation.
The information generated would be helpful both to 
demonstrate the most common areas of impact of particu-
lar hip surgery interventions and to identify whether or not 
the surgical interventions have impacted positively on 
areas of greatest concern to patients or whether there are 
areas important to the patient which remain unaffected. 
This may also show whether, and which, patients fully 
recover (for example, those with an early diagnosis and 
speedy hip conservation surgery) and who may remain 
least affected by their hip condition for years after the 
surgery.
As with any new or novel measure, further validation 
work remains to be done. Together with more evidence on 
test-retest reliability, there is a need to explore the respon-
siveness to change of the QoLI&C measure. We suggest 
that this should be generated through a prospective, obser-
vational study, undertaken in a routine clinical practice 
context, recruiting participants, ideally, from their first 
post-diagnosis healthcare interaction, following partici-
pants up at least for 12 months post-surgical operation(s). 
This study could also valuably collect data on the way the 
measure is used, both by patients and healthcare practi-
tioners, in treatment decision-making and treatment mon-
itoring, focusing in particular on if, and in what ways, the 
measure enhances patient-clinician discussions and aids 
exploration of the relative benefits of treatment options.
In conclusion, further evidence to support the validity, 
reliability and utility of the QoLI&C measures has been 
generated. We suggest that this supports use of the mea-
sure in clinical practice to aid patient-clinician discussions 
over treatment options, both in primary and secondary 
care, and as a way to monitor changes in the impact of 
hip dysplasia on patients’ everyday lives. The measure 
also had potential to be used in effectiveness studies com-
paring different types of surgical interventions and rehabi-
litation practices.
Table 2 Test–Retest: Correlations
Sub-Scale Pearson’s r (n) Comments
Pain Concerns 0.909 (n=43) Good reliability
Education/Work, Sport and Exercise and Family Relations
● With Physical Intimacy
● Without Physical Intimacy
0.901 (n=21)  
0.892 (n=33)
Good reliability  
Good reliability
Psychological Impact 0.948 (n=33) Good reliability
Quality of Life Impact 0.944 (n=52) Good reliability
Scale
Quality of Life, Impact and Concerns Scale 0.968 (n=21) Good reliability
Other Items
Current Level of Pain 0.981 (n=53) Good reliability
Satisfaction with Care 0.736 (n=50) Acceptable reliability
General Health 0.777 (n=48) Acceptable reliability
Time to Complete Questionnaire 0.845 (n=53) Good reliability
Notes: 1. n represents the number of cases who responded to all items in the sub-scale/scale. 2. Analysis employed the listwise missing value option. The maximum number 
of cases is n=53.
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I confirm that all participants to the study were informed 
about the purpose of the study, online electronic consent 
was obtained and that it was conducted in accordance with 
the Declaration of Helsinki.
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